Tablets & Capsules

2019 Annual Buyers Guide

Issue link: https://www.e-digitaleditions.com/i/1048238

Contents of this Issue

Navigation

Page 56 of 147

Tablets & Capsules November 2018 51 Performance qualification (PQ). Validation documenta- tion that shows equipment consistently produces products that meet predetermined specifications and have suitable quality attributes. Permeability. The degree to which film or foil allows dis- solved substances to pass through; used to describe moisture or oxygen transmission. Phase I. Clinical trial studies in which a new drug product or treatment is administered to a small group of patients or healthy volunteers to evaluate its safety, determine a safe dosage range, and identify any side effects. Phase II. Clinical trial studies in which a new drug product or treatment is administered to a larger group of patients with the disease or condition for which treatment is sought to gauge its effectiveness and to further evaluate its safety. Phase III. Clinical trial studies in which a new drug product or treatment is administered to larger groups of patients to confirm its effectiveness, monitor its side effects, compare it to commonly used treatments, and collect information showing that the new drug product or treatment can be used safely. When this phase is complete, a request for marketing approval can be submitted to the FDA. Phase IV. Human studies performed after the drug product or treatment has been marketed. These studies can be used to gather more information on the drug's effect on various populations, to detect any side effects associated with its long-term use, or to identify additional uses. Physical-chemical identifiers (PCIDs). Inactive ingredients that are added to solid dosage forms and/or packaging and that can be detected and authenticated to deter counterfeit- ing. Ingredients include inks, molecular taggants, pigments, and flavors. Picking. An imperfection caused by powders sticking to a punch surface during tableting, often resulting in voids where letters and numbers with islands (enclosed areas)—such as A, O, P, 6, and 8—used to be. Plasticity. The extent to which a material will deform per- manently without breaking. Plastic flow is time-dependent and is usually preceded by elastic deformation. Highly plas- tic materials in tableting may demonstrate tablet properties dependent on machine speed. Porcine. Originating from pigs; used to describe gelatin made from pig products. Pouch. A flexible package for medications. Pre-lock. Small indentations around the perimeter of a cap- sule cap that keep empty two-piece capsules in a semi-closed position until the capsule filler separates the capsules. Prescription drug. A drug that requires a written order by a medical physician or veterinarian to a pharmacist before dis- pensation or sale. Process analytical technology (PAT). A system for design- ing, analyzing, and controlling manufacturing through timely measurements of critical quality and performance attributes of raw and in-process materials and processes with the goal of ensuring final product quality. Punch cup. The depression, or concavity, of the punch tip. It forms the tablet face. Non-compliance. Failure to take medication as prescribed, to follow a prescribed course of therapy, or to adhere to a regulatory mandate. O Occupational exposure limit (OEL). The upper level of the acceptable concentration of a hazardous substance in workplace air for a particular material or class of materials. The levels are usually set by national authorities and enforced by legislation. Offline analysis. Analysis of a material sample removed from a process and taken to the analyzer. Results determine what adjustments, if any, should be made to the process. Operational qualification (OQ). Validation documentation that shows equipment functions according to specifications in the selected environment. Orally disintegrating tablet (ODT). A drug delivery system that dissolves in seconds when placed on the tongue. The system can be taken without water and improves compliance when patients have difficulty swallowing. Orange peel. An imperfection in the coating of a tablet so named because of its resemblance to the fruit, usually caused by using too much atomizing air. Original pack dispensing (OPD). The act of giving phar- maceutical products to patients without any change to their trade dress. Overcompression. The act of applying excessive compac- tion force to a tablet, often resulting in defects. Overencapsulation. The process of placing a tablet or cap- sule within a capsule. An opaque capsule is often used to conceal an investigational drug during clinical trials so that neither the investigators nor subjects can identify the medi- cation from the placebo or comparator they are administer- ing or ingesting. Overload. A device on a tablet press that protects the tool- ing from too much pressure. Over-the-counter drug (OTC). A drug product that is safe and effective for use without a prescription. Oxygen transmission rate (OTR). The amount of oxygen that passes through packaging film or foil over a unit of time and under specific environmental conditions. P Particle analysis. The process of examining a particle or group of particles to determine their size, shape, or other characteristics. It is usually conducted on a sample rather than the whole bulk of material. Particle engineering. The process of changing the morphol- ogy and/or other physico-chemical properties of a powder, such as by spray drying, hot melt extrusion, or the creation of micro- or nano-particles, usually for the purposes of improving solution rate or solubility for better bioavailability. Particle size distribution. The relative amount of particles present according to spherical diameter, mass, or other unit of measure. Peeling. An imperfection in which a film coating flakes off the tablet core, often because of poor surface tension. g l o s s a r y o f t e r m s

Articles in this issue

Archives of this issue

view archives of Tablets & Capsules - 2019 Annual Buyers Guide